INTRODUCTION
Escherichia coli Nissle 1917 (EcN) is a non pathogenic Gramnegative bacterium belonging to the Enterobacteriaceae family [1] . It is a well-known probiotic strain with multiple beneficial effects on intestinal homeostasis. Firstly, in contrast to other E. coli strains, it does not produce virulence factors, so that it is unable to induce damage to the surface of the intestinal epithelium [2] . Conversely, EcN can stimulate the production of human beta-defensin 2, a molecule that has proven to be crucial in the protection of mucosal barrier against the adhesion and invasion of pathogenic bacterial species [3] . Due to this peculiarity, several in vitro and in vivo studies have demonstrated a protective function of EcN against Salmonella, Shigella, Candida and other invasive bacteria [4] [5] [6] . Furthermore, EcN may restore a damaged epithelium through the modulation of tight junction and zonula occludens proteins [7] . Additionally, this singular bacterial strain may secrete some factors (microcins, adhesins, proteases) that enhance the production of adenosine triphosphate (ATP), thus improving the energy availability [8] . Finally, EcN may modulate the mucosal inflammatory response by a direct action on activated T-lymphocytes. As a consequence, reduced levels of proinflammatory cytokines, such as interleukin (IL)-2, interferon gamma (IFNγ) and tumor necrosis factor alpha (TNFα) have been observed in experimental models, as well as an increase of regulatory cytokines (IL-10, IL-1, IL-8) [9, 10] . For these reasons, EcN has been employed in several clinical trials for the treatment of gastrointestinal disorders [11] , including inflammatory bowel diseases (IBD) [1] , a heterogeneous group of chronic recurrent inflammatory disorders of the gastrointestinal tract [12] . Inflammatory bowel diseases are commonly divided into ulcerative colitis (UC) and Crohn's disease (CD). Two pathogenetic hypotheses are predominant in the current view: a predisposing genetic background and an immune response against the human microbiota [13] [14] [15] . Intestinal microbiota is constituted by a wide variety of bacterial species, and it has been considered as an "organ within an organ" for its extreme variety of strains and ability to control the local immunity and response to antigens [16] . On this basis, the possibility that a pharmacological modulation of intestinal microbiota could mirror the outcome of IBD and other gastrointestinal disorders has been investigated with increasing success [17] [18] [19] [20] .
The aim of the present systematic review with meta-analysis was to investigate the role of EcN administration in patients suffering from UC, focusing on the effectiveness in inducing and maintaining the remission phase and the safety profile.
METHOD Eligibility criteria and study selection
Methods of analysis and inclusion criteria were based on "Preferred Reporting Items for Systematic reviews and MetaAnalyses" (PRISMA) recommendations [21] , and a PICOS checklist has been enclosed (see Supplementary material). Only randomized clinical trials were included, while review articles, experimental in vivo or in vitro studies and non randomized trials were excluded. Abstracts were excluded.
Data collection process
A literature search was performed in June 2015. Relevant publications were identified by a research in PubMed, MEDLINE, Science Direct and EMBASE. The search terms were Escherichia coli, Nissle, treatment, inflammatory bowel disease and ulcerative colitis. We used the following string: [(ulcerative colitis) AND (Escherichia coli OR E coli OR EcN OR Nissle)]. Titles and abstracts of papers were screened by two reviewers (G.L. and E.I.). Studies were independently prescreened in blind for relevance by the two reviewers using full reports. Discussion put an end to any disagreements. Successively, data were extracted from the relevant studies by one reviewer and checked by a second reviewer, and thus inserted into dedicated tables. A third reviewer (M.P.) came to a decision about any disagreements.
Reviewers independently abstracted from each paper the following data: (i) year of publication, (ii) country where the study was performed, (iii) single-or multicentre study, (iv) study design, (v) number of patients included, (vi) methods of randomization, (vii) success rate expressed as intention to treat (ITT) for induction and maintenance of remission, (viii) side effects.
Risk of bias
To ascertain the validity of eligible randomized trials, pairs of reviewers working independently and with adequate reliability determined the adequacy of randomization and concealment of allocation, blinding of patients, health care providers, data collectors, and outcome assessors. Additionally, we provided funnel plots to determine the risk of publication bias: absence of significant publication bias occurred when symmetry in the graph appeared.
Summary measures and aim of the meta-analysis
The end-point was to compare the administration of EcN strain in patients with UC, in comparison to a control group, represented either by placebo or mesalazine administration. The outcomes extracted for the meta-analysis were the success rates for induction of remission, relapse rates and side effects. These data have been expressed as percentages.
Planned methods of analysis
Data on remission achievement or maintenance, expressed as ITT, and side effects were extracted from the studies. Odd ratios (OR), pooled OR and 95% confidence intervals (CI) were calculated, based on the Mantel-Haenszel method. Data were entered into the RevMan 5.3 software (The Nordic Cochrane Centre, Copenhagen, Denmark) (Cochrane library). A p value <0.05 was considered statistically significant. Heterogeneity was assessed by using the χ 2 and I 2 statistics. In particular, heterogeneity was considered to be present if the χ 2 test delivered a p < 0.05 and, therefore, I 2 statistic was used to quantify the proportion of heterogeneity between the studies. In the presence of heterogeneity, a revision of included studies was carried out to assess the main reason explaining the phenomenon and, therefore, the subgroup analysis was performed. Only if this attempt failed, a random effects model was employed, otherwise a fixed effects model was adopted [22] . Finally, the Jadad scale was selected in order to evaluate the methodological quality of eligible trials [23] . A score ≥ 3 points indicated an adequate quality of the trial.
RESULTS

Study selection
The literature search identified 299 articles, of which only 6 met the inclusion criteria after the selection by the reviewers. The flow diagram of this systematic review is displayed in Fig. 1 . The main characteristics of the six studies [24] [25] [26] [27] [28] [29] are summarized in Table I . All studies but one [29] were performed on the adult population. The dose of EcN was the same in all studies. In four studies [24, 25, 28, 29] , EcN was compared to mesalazine, while in the remaining two [26, 27] it was compared to a placebo. In one study [26] , EcN was given via enema for proctitis or proctosigmoiditis. Overall, 719 patients were recruited for the meta-analysis; 390 were assigned to the study group and 329 to the control group.
The quality of eligible trials according to the Jadad scale is reported in Table II . All studies had a score equal or greater than 3, resulting in a good quality of the trial.
Induction of remission
Only three studies evaluated the ability of EcN to induce remission [26] [27] [28] . EcN was able to induce remission in 61.6% of cases (106 out of 172), while in the control group the remission was achieved in 69.5% of cases (66 out of 95), Fig. 2 .
Maintenance of remission
The maintenance of remission was evaluated in four studies [24, 25, 28, 29] . In all cases, the control groups received the standard of care (mesalazine). In the overall analysis, a relapse of the disease occurred in 36.8% (82 out of 223) in the EcN 
.91, p=0.82 and I2=0%), therefore a fixed effects model was adopted. The forest plot of the present analysis is shown in Fig. 3 .
Side effects
All the six studies investigated side effects, which were observed in 35.9% of the EcN group and in 26.1% in the control group. Pooled OR was 1.44, 95% CI = 0.80-2.59, p=0.22, as displayed in Fig. 4 . Therefore, the rates of side effects were comparable between the two groups. We adopted a random effects model, since a moderate heterogeneity was detected (χ 2 =7.7, p=0.1 and I 2 =48%). The most common adverse reactions were diarrhea and bloating, more common in the EcN group. Figure 5 shows the funnel plots of the three cited comparisons (induction of remission, maintenance of remission and side effects, respectively), demonstrating the symmetry of the study distribution, thus excluding the possibility of publication bias.
Risk of bias in interventional studies and heterogeneity
Heterogeneity. A high grade of heterogeneity was found between the studies. Several factors may contribute to this phenomenon, and they may be summarized as follows: i) a discrepancy in the composition of the control group, since in two studies a placebo [26, 27] and in the other four mesalazine were assumed, ii) the different dose of mesalazine, iii) one study was performed on a pediatric population [29] , iv) in one study EcN was given by enema [26] and v) the different duration of the follow up, ranging from 12 weeks to 12 months. All these factors could represent limitations for the meta-analysis, despite we suppose that the exclusion of the study on pediatric population could be a source of publication bias.
DISCUSSION
The use of probiotics in the treatment of UC has been postulated and investigated in several trials with different results [30] . Current guidelines [31] report that single probiotic strains are not effective in inducing the remission, according to various clinical trials [32, 33] . Their use in IBD is widespread for the safety profile although not all strains are equally effective. A probiotic mixture called VSL#3TM has been proven to be successful for induction and maintenance of remission in children with active UC, in a 1-year placebo-controlled, double-blind study [34] . The same mixture is considered as a gold standard for the treatment of pouchitis, and therefore it is advised by guidelines [31, 35, 36] . Additionally, EcN is recommended by the guidelines as an alternative to mesalazine for the maintenance of remission in UC. This recommendation was based on the results of four trials, which were available at the time of guideline elaboration. The present review encloses two more recently published studies which permitted a meta-analysis on this topic, which represents therefore the first one in the literature.
A first relevant finding of our analysis is that EcN is as effective as the regimen used in controls for induction of remission (OR: 0.92; p=0.93). Indeed, in two of the three analyzed studies, the control groups received a placebo. On this basis of the verification of the null hypothesis, it may be argued that EcN is not superior to a placebo in the remission phase induction. The only study [28] that compared EcN to On the other hand, the evaluation of the maintenance of remission was performed in comparison to mesalazine in all studies. This detail allows to draw more solid conclusions, due to the absence of heterogeneity between the studies (χ 2 =0.91, p=0.82 and I 2 =0%). In this comparison EcN was as successful as mesalazine in preventing the relapse, with an OR=1.07, p=0.74. This finding represents the statistical validation of guideline statements regarding this topic.
A peculiar observation concerns the extension of the disease. In two studies [24, 25] , with a large proportion of patients with proctitis and proctosigmoiditis enrolled, EcN demonstrated a high effectiveness (Fig. 3) . Moreover, in the only study in which EcN was administered by enema for proctosigmoiditis, its efficacy was better than a placebo [26] . For these reasons, we may hypothesize that EcN could be more effective for the treatment of distal UC.
A first limitation of our meta-analysis is related to the small number of eligible studies. This detail may be a limit, since a solid conclusion could not be drawn, and further high-quality trials are needed. The second limitation is related to the high heterogeneity of the included trials, which is another drawback in order to perform a solid comparison between studies. We have underlined that this finding may be explained by a discrepancy in the composition of the control group, by the different dose of mesalazine, the age of enrolled patients, the route of EcN administration and the different duration of the follow up, ranging from 12 weeks to 12 months. Moreover, in the three studies analyzing the induction of remission, one study compared EcN to placebo, one to mesalazine and one study to placebo plus standard of care (which for some patients also included mesalazine), thus contributing to the high heterogeneity.
The present meta-analysis could provide some key points regarding the treatment of UC with EcN. First, EcN is equivalent to mesalazine in preventing disease relapse. Second, its use in inducing the remission cannot be recommended. However, other studies may be helpful to support this assertion, since the level of evidence for probiotic use in inducing remission is low (level 5 according to guidelines) [31] . In particular, the use of EcN as an add-on treatment to traditional therapy could represent an interesting field of investigation. Finally, EcN could be advised especially for proctitis and proctosigmoiditis, but this proposition needs to be investigated more in depth.
CONCLUSION
E. coli Nissle 1917 is a valid probiotic for UC treatment and its use could represent an effective option even if indications need to be better detailed through new trials able to provide a more reliable support for a further meta-analysis. 
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